The role of oncolytic viruses in the treatment of melanoma
CAY Bayan, AT Lopez, RD Gartrell… - Current oncology …, 2018 - Springer
Abstract Purpose of Review Oncolytic virotherapy is a new approach to the treatment of
cancer and its success in the treatment of melanoma represents a breakthrough in cancer …
cancer and its success in the treatment of melanoma represents a breakthrough in cancer …
Quantitative analysis of immune infiltrates in primary melanoma
Novel methods to analyze the tumor microenvironment (TME) are urgently needed to stratify
melanoma patients for adjuvant immunotherapy. Tumor-infiltrating lymphocyte (TIL) …
melanoma patients for adjuvant immunotherapy. Tumor-infiltrating lymphocyte (TIL) …
[HTML][HTML] Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy
A Hanoteau, JM Newton, R Krupar, C Huang… - … for immunotherapy of …, 2019 - Springer
Background Chemoradiotherapy (CRT) remains one of the most common cancer treatment
modalities, and recent data suggest that CRT is maximally effective when there is generation …
modalities, and recent data suggest that CRT is maximally effective when there is generation …
[HTML][HTML] Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition
JM Newton, A Hanoteau, HC Liu, A Gaspero… - … for immunotherapy of …, 2019 - Springer
Abstract Background Immune checkpoint inhibitors (ICIs) for solid tumors, including those
targeting programmed cell death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 …
targeting programmed cell death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 …
Linking transcriptomic and imaging data defines features of a favorable tumor immune microenvironment and identifies a combination biomarker for primary …
Patients with resected stage II-III melanoma have approximately a 35% chance of death from
their disease. A deeper understanding of the tumor immune microenvironment (TIME) is …
their disease. A deeper understanding of the tumor immune microenvironment (TIME) is …
Characterization and spatial localization of the tumor immune microenvironment in metastatic uveal melanoma.
KM Komatsubara, RD Gartrell, CA Bayan, JS Pradhan… - 2018 - ascopubs.org
9570 Background: Uveal melanoma (UM) is a rare subset of melanoma that is resistant to
immune checkpoint blockade. High density of macrophages (Mϕ) and TILs is associated …
immune checkpoint blockade. High density of macrophages (Mϕ) and TILs is associated …
Quantitative multiplex immunofluorescence to identify candidate biomarkers of response to anti-PD1 in metastatic melanoma.
CA Bayan, RD Gartrell, KM Komatsubara, JS Pradhan… - 2018 - ascopubs.org
e21600 Background: Predictive biomarkers for stratification of treatment with immunotherapy
are urgently needed. Quantitative multiplex immunofluorescence (qmIF) allows for staining …
are urgently needed. Quantitative multiplex immunofluorescence (qmIF) allows for staining …
Characterization of the immune landscape in stage II-III melanoma using qIF
Background: The tumor microenvironment plays a crucial role in cancer progression, often
supporting immune evasion. This is of particular importance in melanoma, where immune …
supporting immune evasion. This is of particular importance in melanoma, where immune …
Radiation, immune checkpoint inhibition, and modulation of the tumor immune microenvironment promotes immunologic rejection of established HPV-associated …
JM Newton, A Hanoteau, HC Liu, A Gaspero… - Cancer Research, 2019 - AACR
Immune checkpoint inhibitors (ICI), including those targeting cytotoxic T-lymphocyte-
associated-antigen-4 (CTLA-4) and programmed cell death receptor-1 (PD-1), have shown …
associated-antigen-4 (CTLA-4) and programmed cell death receptor-1 (PD-1), have shown …
Quantitative multiplex immune fluorescence to reveal the impact of chemoradiation therapy on modulation of the immune micro-environment of pancreatic ductal …
4122 Background: Patients with advanced pancreatic ductal adenocarcinoma (PDA)
continue to have median survival under one year and to date immunotherapy has largely …
continue to have median survival under one year and to date immunotherapy has largely …